Catheter-related Bloodstream Infections Market by Drug Class, Route of Administration, Indication, Distribution Channel

Description

List of Tables

[187 Pages Report] The Catheter-related Bloodstream Infections Market size was estimated at USD 1.64 billion in 2023 and expected to reach USD 1.74 billion in 2024, at a CAGR 5.88% to reach USD 2.46 billion by 2030.

Catheter-related bloodstream infections (CRBSIs) refer to infections acquired when bacteria and fungi enter the bloodstream through a central line or catheter, which are tubes placed in large veins for medical treatments. Increased patient admissions in hospitals and clinical settings that utilize intravenous treatments have significantly boosted the demand for advanced catheters designed to reduce the incidence of catheter-related bloodstream infections (CRBSIs). The rising prevalence of these infections globally underscores the need for products that guarantee safer delivery of intravenous medicines, thus propelling market growth. However, strict regulations related to drugs and product recalls are the significant challenge faced by the key companies. Moreover, there is a notable trend of partnerships and amalgamations among significant companies that specialize in medical devices and hospital care solutions. These collaborations aim to innovate and enhance catheter technologies that prevent infections, resulting in expanded distribution networks and improved product offerings, which in turn enhance market reach and penetration.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.64 billion
Estimated Year [2024]	USD 1.74 billion
Forecast Year [2030]	USD 2.46 billion
CAGR (%)	5.88%

Regional Insights

The Americas, particularly the United States and Canada show differing degrees of consumer needs and purchasing behaviors due to diversity in healthcare system structures and policies. The United States has a significant rate of medical technology adoption, which includes advanced CRBSI prevention technologies like antimicrobial catheters and chlorhexidine dressings. Substantial funding is being allocated to research on CRBSIs, which will lead to ongoing clinical trials and developments in infection prevention. The Centers for Disease Control and Prevention (CDC) also plays a pivotal role in setting guidelines and protocols. At the same time, the EMEA region shows varied responses to CRBSIs, reflecting different healthcare infrastructure levels, funding, and public health policies. Countries within the EU benefit from cooperative healthcare standards and shared research initiatives. Ongoing research focuses on the technological and procedural aspects of CRBSI prevention. European Commission frameworks support research collaborations across member states to address HAIs. Moreover, in the Asia Pacific region, countries including China, Japan, and India are key players in the healthcare sector, profoundly impacted by catheter-related bloodstream infections (CRBSIs). These infections are especially critical due to the region's high population densities and varying healthcare infrastructure. Recent regional patents for CRBSI prevention technology emphasize improvements in catheter design and antimicrobial applications. Investments are robust in healthcare improvements, including infection control protocols driven by the government.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Catheter-related Bloodstream Infections Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Increasing concerns about intravenous bacterial infections and the need for effective treatment options
- Growing number of educational campaigns for awareness of catheter-related bloodstream

Market Restraints
- Strict government regulations related to drug approvals and cases of product recalls

Market Opportunities
- Favorable government initiatives and policies for bacterial infectious diseases
- Advancements in the drug delivery and ongoing R&D activities for the novel drug development

Market Challenges
- Allergens and significant health concerns associated with catheter-related bloodstream infections medications

Market Segmentation Analysis
- Drug Class: Extensive utililzation of Cefazoline and Cloxacillin medication in the treatment of bacterial infections caused by catheter
- Indication: Growing focus on the effective management and the prevention and treatment of viral & parasitic infections

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Catheter-related Bloodstream Infections Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Catheter-related Bloodstream Infections Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Citius Pharmaceuticals Announces Completion of Phase 3 Trial Enrollment for Mino-Lok, Aiming to Salvage Infected Catheters

Citius Pharmaceuticals completed patient enrollment for the pivotal Phase 3 clinical trial of Mino-Lok, an antibiotic therapy designed to treat catheter-related bloodstream infections (CRBSIs). This significant milestone marks a crucial step towards providing a potentially life-saving treatment option to salvage infected central venous catheters (CVCs), thereby avoiding the need for their removal and replacement. This therapeutic approach aims to enhance patient outcomes and seeks to reduce healthcare costs and procedural complications associated with the current standard practice of catheter replacement. [Published On: 2024-01-02]

BD Partners with Bactiguard to Enhance Global Access to Infection-Preventing Foley Catheters

Becton Dickinson and Company (BD) has secured an exclusive global licensing partnership, excluding China, with Bactiguard for its innovative Bactiguard-coated Foley catheters. This agreement marks a significant expansion in the distribution of Bactiguard's infection prevention technology, which is integrated into Foley catheters to reduce the risk of catheter-related bloodstream infections. This partnership aims to enhance patient outcomes by broadening the availability of these advanced medical devices, potentially impacting healthcare standards globally. [Published On: 2023-12-14]

FDA Approval of DefenCath Marks a Significant Step in Catheter-Related Bloodstream Infection Prevention for Hemodialysis Patients

CorMedix Inc. received U.S. Food and Drug Administration (FDA) approval for DefenCath, a catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in adult hemodialysis patients. This approval underscores the effectiveness of DefenCath in reducing the risks of CRBSIs, a common and serious complication that affects patients with central venous catheters. DefenCath's active ingredient is taurolidine, which is known for its antimicrobial properties and significantly enhances patient safety during hemodialysis. [Published On: 2023-11-15]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Catheter-related Bloodstream Infections Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Catheter-related Bloodstream Infections Market, highlighting leading vendors and their innovative profiles. These include Advacare Pharma, AstraZeneca PLC, Bactiguard AB, Becton, Dickinson and Company, CorMedix Inc, Fresenius Medical Care AG, Glenmark Pharmaceuticals Ltd., IntegraDose Compounding Services, LLC, Johnson & Johnson Services, Inc, JoinHub Pharma, Lupin Ltd., Lyka Hetero Healthcare Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, TauroPhar GmbH, and Xellia Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Catheter-related Bloodstream Infections Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Cefazoline
- Ceftazidime
- Cloxacillin
- Daptomycin
- Echinocandin
- Teicoplanin
- Vancomycin

Route of Administration
- Injectable
- Oral

Indication
- Bacterial Infections
- Fungal Infection
- Viral & Parasitic Infections

Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-5D693B46C67B

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing concerns about intravenous bacterial infections and the need for effective treatment options
  - 5.1.1.2. Growing number of educational campaigns for awareness of catheter-related bloodstream
- 5.1.2. Restraints
  - 5.1.2.1. Strict government regulations related to drug approvals and cases of product recalls
- 5.1.3. Opportunities
  - 5.1.3.1. Favorable government initiatives and policies for bacterial infectious diseases
  - 5.1.3.2. Advancements in the drug delivery and ongoing R&D activities for the novel drug development
- 5.1.4. Challenges
  - 5.1.4.1. Allergens and significant health concerns associated with catheter-related bloodstream infections medications
5.2. Market Segmentation Analysis
- 5.2.1. Drug Class: Extensive utililzation of Cefazoline and Cloxacillin medication in the treatment of bacterial infections caused by catheter
- 5.2.2. Indication: Growing focus on the effective management and the prevention and treatment of viral & parasitic infections
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Catheter-related Bloodstream Infections Market, by Drug Class

6.1. Introduction
6.2. Cefazoline
6.3. Ceftazidime
6.4. Cloxacillin
6.5. Daptomycin
6.6. Echinocandin
6.7. Teicoplanin
6.8. Vancomycin

7. Catheter-related Bloodstream Infections Market, by Route of Administration

7.1. Introduction
7.2. Injectable
7.3. Oral

8. Catheter-related Bloodstream Infections Market, by Indication

8.1. Introduction
8.2. Bacterial Infections
8.3. Fungal Infection
8.4. Viral & Parasitic Infections

9. Catheter-related Bloodstream Infections Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies

10. Americas Catheter-related Bloodstream Infections Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Catheter-related Bloodstream Infections Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Catheter-related Bloodstream Infections Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Citius Pharmaceuticals Announces Completion of Phase 3 Trial Enrollment for Mino-Lok, Aiming to Salvage Infected Catheters
- 13.3.2. BD Partners with Bactiguard to Enhance Global Access to Infection-Preventing Foley Catheters
- 13.3.3. FDA Approval of DefenCath Marks a Significant Step in Catheter-Related Bloodstream Infection Prevention for Hemodialysis Patients
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio